graft-versus-host disease

(redirected from GVHD)
Also found in: Medical, Acronyms.
Related to GVHD: HLA

graft-ver·sus-host disease

(grăft′vûr′səs-hōst′, -səz-)
A condition in which cells from the transplanted tissue of a donor initiate an immunologic attack on the cells and tissue of the recipient.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

graft′-ver`sus-host′ disease`

a reaction in which the cells of transplanted tissue immunologically attack the cells of the host.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Significance of Phase 2 Data in Prevention of Acute GVHD
Acute GVHD:Develops in the first 100 or so days after transplant but may occur later.
Biopharmaceutical company Incyte Corporation (Nasdaq:INCY) revealed on Friday the receipt of the first and only approval from the US Food and Drug Administration (FDA) for Jakafi (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and paediatric patients 12 years and older.
It is well documented, especially within 5-10 days after initiating a conditioning regimen, mostly with radiation-based myeloablative regimens containing the chemotherapeutic agents busulfan, etoposide, melphalan, and methotrexate, in addition to the use of methotrexate-containing GvHD prophylaxis (10).
Graft-versus-host disease (GvHD) is a complication that can occur after a bone marrow transplant or similar procedure, when the donor's immune cells attack the recipient of the transplant.
Clinically, GI GVHD presents with nonspecific GI symptoms including nausea, vomiting, oropharyngeal mucositis, dysphagia, diarrhea, and GI bleeding.
Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon in these key markets to advance the clinical development for the prevention of chronic GvHD in SCT.
Ocular manifestations can be found in more than 60% of GVHD patients [9].
The degree of HLA disparity between donor and recipient is a well-known and widely accepted independent risk factor for GVHD development [2].
Improvements were achieved due to molecular-based HLA typing, conditioning regimens, prevention of graft-versus-host disease (GvHD) and better supportive care.